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CHAPTER 1: INTRODUCTION
Innovation and development of new technologies have revolutionized cancer care by
refining diagnosis, advancing treatment, and improving prognosis of many cancers
previously associated with substantial morbidity and mortality. For example, the
introduction of radiation therapy in conjunction with breast conserving surgery replaced
previous dogma that insisted on radical and oftentimes disfiguring surgery in women with
early stage breast cancer. 1-3 As such, the evolution of cancer technology has had a
substantial impact in improving patient outcomes, safety, and quality of life.

As newer cancer technologies diffuse into clinical practice, it is important to rigorously
evaluate both factors that drive adoption and the implications of such adoption in terms
of clinical effectiveness, costs, and overall value. Such evaluation is critical to help
inform clinical decision making and to ensure that high-quality and value-oriented care is
achieved. Many factors can affect the adoption of new cancer technologies such as
clinical evidence, hospital factors, patient and physician preferences, reimbursement
incentives, as well as regional and health system characteristics. Given that newer
cancer technologies are often more expensive and reimbursed more heavily than the
standard of care, there have been questions about cost-conscious care and non-clinical
factors driving adoption. After the initial adoption of newer cancer technologies, it is
important to understand their implications in terms of costs, quality, and cost-effective
care. These implications are often complicated by the fact that many newer cancer
interventions often disseminate into clinical practice during times when there is scant
comparative effectiveness data supporting their benefit. Using formal cost-effectiveness
analysis offers one standardized way to evaluate existing trial tested cancer
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technologies and allows for estimating the incremental value of various cancer
treatments relative to treatment guidelines. In addition, cost-effectiveness analysis is
also valuable in assessing how much better newer technologies would have to be, and
in particular those technologies that have been adopted in the absence of trial based
evidence. Thus, an investigative framework that first evaluates factors that promote
adoption of new cancer treatments and then assesses the cost-effectiveness of such
adoption provides one way to longitudinally evaluate new technologies during different
stages of clinical implementation.

When considering factors that drive adoption of newer technologies, non-clinical factors
are particularly important to consider because the combination of higher reimbursements
and limited clinical evidence raises questions about incentives driving their use. Hospital
level factors such as ownership status is one example of a non-clinical factor that may
drive adoption and use. Hospitals play an integral role in investing in new technological
infrastructure and have real incentives to attract patients and secure financial viability.
Thus, financial incentives related to hospital ownership status may be one factor that
promotes the adoption of new cancer treatments. Financial incentives, in general, have
been speculated as a contributing factor to increased adoption of highly reimbursed
therapies in prostate and breast cancer care. 4,5 However, little is known about the role of
hospital ownership status on the adoption of highly reimbursed cancer therapies.

In addition to financial incentives, enthusiasm and marketing of newer treatments may
also affect the perception of newer cancer care technologies among both patients and
providers and impact use and practice patterns. For example, enthusiasm for novel
therapies may lead to new technologies being perceived as better than the current
standard of care despite a lack of evidence demonstrating increased benefit. In addition,
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there may also be a notion that more care with newer technologies is better care and
associated with improved outcomes. However, given the limited clinical evidence during
early phases of adoption, the perception of new cancer technologies may not always be
grounded with data proving their benefit. Therefore, it is important to comprehensively
evaluate new technologies and understand factors that drive adoption such that new
therapies are implemented responsibly and appropriately in clinical practice.

After initial adoption of these newer therapies, assessing the cost-effectiveness of these
technologies offers one way to measure value and compare various newer treatments
on a standardized scale. On the one hand, while costs may be higher, new
technologies have the potential to improve patient quality of life and outcomes. However,
in some settings new technologies have increased costs while having marginal or
sometimes questionable benefit on clinical outcomes.6 This may be particularly true in
the early phase of adoption, when data on effectiveness is scant. Thus, assessing the
cost-effectiveness of both the standard of care and of newer treatment options can help
inform clinical decision making for both patients and providers and offer guidance
towards value-oriented cancer care.

Towards this end, radiation therapy is a germane cancer technology to study because
many new modalities are disseminating into clinical practice when there is scant
evidence supporting their benefit. More specifically, radiation therapy in the treatment of
older women with early stage breast cancer is a meaningful scenario to consider
because use of radiation in this population confers no survival advantage, provides
minimal benefit, and can be safely omitted according to current trial-based guidelines. 710

Moreover, newer radiation modalities have been increasingly adopted in the treatment

of older women despite guidelines and trial-based evidence.11,12 These patterns of care
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with newer radiation modalities raise questions about appropriate care, overuse, and
cost-effective care. Two examples of newer breast radiation therapy modalities include
brachytherapy and intensity modulated radiation therapy (IMRT). Modern breast
brachytherapy involves catheter-based implantation of devices in the breast surgical
cavity with later after-loading of high dose rate radiation sources to deliver radiation
internally.13 Breast brachytherapy condenses the treatment course from 5-6 weeks to 1
week. IMRT, on the other hand, is a variant of EBRT but allows for improved dose
homogeneity and avoidance of some critical structures.14,15 These newer therapies have
the potential benefits of reducing treatment related acute side effects, reducing late
toxicity, and decreasing toxicity to surrounding breast, heart, and lung.13,16-18 However,
clinical trial data comparing these newer modalities to the standard of care with external
beam radiation has yet to mature with some preliminary studies suggesting that the risks
may outweight potential benefit.19,20

Thus, determining factors that drive adoption and assessing the cost-effectiveness of
newer and unproven radiation therapy modalities has important consequences in
understanding and informing clinical decision making. Comparing newer modalities
compared to the standard of care using cost-effectiveness analysis further enables a
standardized method to assess potential value of newer radiation modalities and provide
a quantitative framework that can speculate either how costly or effective newer
modalities would have to be in order to be cost-effective. Therefore, we set out to
determine the effect of hospital ownership status on the use of brachytherapy in the
treatment of older women with early stage breast cancer. In a second study, we
developed a decision analytic model to determine the incremental cost-effectiveness of a
trial tested radiation therapy modality using external beam compared to guideline based
treatment with no radiation in older women with early stage breast cancer. Finally, we
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determined the cost-effectiveness of newer radiation modalities (IMRT and
brachytherapy) in this patient population and determined how much more effective they
would have to be in order to be cost-effective.
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CHAPTER 2: HOSPITAL OWNERSHIP STATUS AND USE OF BRACHYTHERAPY
2.1: ABSTRACT
BACKGROUND: Because the benefits of adjuvant radiation therapy (RT) for breast
cancer decrease with increasing age, the use of expensive and unproven RT modalities
such as brachytherapy in the treatment of older women has been questioned. In
particular, patients and policy makers may be concerned that for-profit hospitals might
be more likely to use therapies with higher reimbursements. Among both younger and
older Medicare beneficiaries with breast cancer, we examined whether hospital
ownership status is associated with use of adjuvant brachytherapy.
METHODS: We conducted a retrospective study of female Medicare beneficiaries aged
66-94 years old receiving breast-conserving surgery for invasive breast cancer in 2008
and 2009. We assessed the relationship between hospital ownership and receipt of
brachytherapy, as well as overall RT (i.e. brachytherapy or whole breast irradiation
(WBI)) using hierarchical generalized linear models.
RESULTS: The sample consisted of 35,118 women, 8.0% of whom had undergone
surgery at for-profit hospitals. Among patients who received RT, those who underwent
surgery at for-profit hospitals were significantly more likely to receive brachytherapy
(20.2%) than patients treated at not-for-profit hospitals (15.2%; Odds Ratio (OR) for
profit vs. not-for profit: 1.50, 95% CI: 1.23-1.84). Among women 66-79 years old, there
was no relation between hospital profit status and overall RT use. However, among
women age 80-94 years old, receipt of surgery at a for-profit hospital was significantly
associated with higher overall RT use (1.22; 1.03-1.45) and brachytherapy use (1.66;
1.18-2.34), but not WBI use (1.14; 0.96-1.36)
CONCLUSIONS: Medicare beneficiaries undergoing breast-conserving surgery at forprofit hospitals were more likely to receive brachytherapy, a newer, less proven, and
more expensive technology. Among the oldest women, who are least likely to benefit
from RT, care at a for-profit hospital was associated with higher overall RT use, which
was explained by higher utilization of brachytherapy in this subgroup
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2.2: INTRODUCTION
The adoption of new unproven technologies and the associated increase in costs of
cancer care has raised concerns about inappropriate care and overuse, especially in
light of current value-oriented healthcare initiatives.21-24 Many factors may affect the
adoption of newer medical technologies including patient and physician preferences,
reimbursement incentives, clinical evidence, and regional health system factors.25-28
Hospitals play a major role in the adoption of new technologies, due to their ability to
invest in infrastructure, their central role in the treatment of many conditions, and their
being the focus of payer efforts to enhance quality and control costs. Hence, it is
important to understand how hospital factors, such as ownership status, affect the
adoption of new technologies.

The effect of ownership status is particularly relevant in clinical scenarios where
evidence regarding treatment benefit is less definitive, and clinical decision-making is
more discretionary. In this setting, hospitals owned by for-profit entities, which must
return value to investors, may be more likely to encourage the adoption of highly
reimbursed interventions. While both for-profit and not-for-profit hospitals have financial
incentives to emphasize revenue-generating procedures, for-profit hospitals may be
more responsive to these incentives given their fiduciary interests.29-31 For example, forprofit hospital ownership has been associated with increased use of cardiac
revascularization interventions independent of clinical outcome.31 Similarly, receipt of
care at for-profit hemodialysis centers has been associated with increased erythropoietin
drug dosing in excess of recommendations from clinical guidelines.32 However, these
studies focused on the use of widely used treatment strategies that had already
disseminated into clinical practice with evidence-based guidelines in place. Little is
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known about the effect of hospital ownership status on the adoption of new medical
technologies that are reimbursed at higher rates than existing technologies.33

Breast brachytherapy for women with early stage breast cancer is an excellent example
of a newer therapy with scant comparative effectiveness data and higher
reimbursements compared to the standard whole breast irradiation (WBI). Given current
trial based guidelines that recommend that radiation therapy using WBI after breast
conserving surgery can be omitted in older women given limited clinical benefit, the use
of a newer and unproven radiation modality, brachytherapy, raises questions about
appropriate care and factors driving its adoption.4,34,35 Although breast brachytherapy
has diffused into clinical practice, some recent data suggest that harms may actually
outweigh the benefits.13,19,20,36-39 Furthermore, brachytherapy is more highly reimbursed
than the standard of care, and some authors have suggested that financial interests are
driving the adoption of brachytherapy in clinical practice. 4,40-42 It remains unknown
whether care at a for-profit hospital is associated with the receipt of brachytherapy.

It is also important to consider how the adoption of brachytherapy might affect overall
use of adjuvant radiation therapy (RT). That is, after disseminating into clinical practice
in either profit setting, brachytherapy may substitute for the standard of care, WBI,
without any increase in the overall use of RT. Alternatively, enthusiasm for
brachytherapy could expand the pool of women who are assessed to be suitable
candidates for RT and instead complement the standard of care, thereby increasing
overall RT use. In this context, financial incentives and increased reimbursement for
brachytherapy may lead to a higher overall use of RT. This may be particularly true
among older women, and especially those above age 80 years, for whom the benefit of
RT diminishes and thus may be more subject to provider preferences and discretionary
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judgment.7-9,43 It remains unknown whether care at a for-profit hospital is associated with
brachytherapy use as a substitute for standard RT or associated with a higher likelihood
of RT use overall.

To further our understanding of the relation between hospital ownership status and
cancer care, we used national Medicare data to assess the relation between for-profit
hospital ownership and the adoption of brachytherapy among Medicare beneficiaries
with breast cancer receiving breast-conserving surgery (BCS). We hypothesized that
among women receiving adjuvant RT, those who had undergone BCS at a for-profit
hospital would be more likely to receive brachytherapy. We also assessed whether
women undergoing BCS at for-profit hospitals would be more likely to receive RT overall.
That is, we hypothesized that the use of brachytherapy in for-profit hospitals increases
the proportion of women who are receiving RT, rather than simply substituting for WBI.
We also hypothesized that this relation between brachytherapy and overall RT use
would be stronger among older women, the group for whom RT is more discretionary.
2.3: METHODS
Data Source and Study Sample
Using the Centers for Medicare and Medicaid Services Chronic Condition Warehouse
(CCW) database, we identified a sample of female Medicare beneficiaries between ages
66-94 years who received BCS and adjuvant RT for invasive breast cancer in 2008 and
2009.44,45 The CCW is a national database that contains 100% of fee-for-service
Medicare claims for inpatient and outpatient institutional and non-institutional services for
patients with certain chronic conditions. We identified beneficiaries with invasive breast
cancer by the International Classification of Diseases, 9th revision (ICD-9) diagnosis
code (174.x). Receipt of brachytherapy or other forms of adjuvant RT (external beam,
intensity modulated) was identified according to Healthcare Common Procedure Coding
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System codes (HCPCS; Appendix 2.1). We only included women who received BCS
between January 2008 and June 2009 and were enrolled in fee-for-service Medicare
Parts A and B during the study period. Approximately 93% of all Medicare beneficiaries
are enrolled in both Parts A and B.46 Women were excluded from this sample if they
received an ICD-9 diagnosis code for any other cancer (including ductal carcinoma in
situ) in the 9 months prior through 6 months after BCS (Appendix 2.2). This study used
de-identified patient data and was classified by the Yale Human Investigation Committee
as nonhuman subjects research and was exempted from a full review.

Radiation Therapy
Patients with any HCPCS codes indicative of brachytherapy treatment were considered
to have received brachytherapy. Patients with at least four HCPCS codes indicative of
the delivery of WBI with external beam RT (either standard or intensity modulated) were
considered to have received WBI. In order to capture all patients for whom the decision
was made to provide brachytherapy as a component of their therapy, patients with codes
for both brachytherapy and WBI (less than 0.5% of the total sample) were assigned to
the brachytherapy group.

Construction of Variables
Patient characteristics included age, race, year of surgery, residence in a metropolitan
county based on Core Based Statistical Areas, and median household income at the zip
code level. Clinical characteristics such as comorbid conditions, tumor laterality, lymph
node evaluation, and receipt of chemotherapy were assessed using HCPCS and ICD-9
codes from the Medicare claims (Appendix 2.1). As proxies for access to care, we
accounted for each of the following variables in the year prior to surgery: any hospital
admission, screening mammogram, receipt of a flu shot, or primary care physician visit.
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Comorbid conditions previously found to be associated with survival in non-cancer
patients were assessed by searching claims in the 12 months through one month prior to
BCS.47 We included ICD-9 diagnosis codes that were on an inpatient claim or ≥2
outpatient/physician claims billed >30 days apart.

For each patient, we identified the hospital at which BCS was performed using the
Medicare provider number. Hospital ownership was determined from the Medicare
Hospital General Information dataset which is a self-reported measure by hospitals
during enrollment with the Centers for Medicare and Medicaid Services.48 All hospitals
listed as ‘Proprietary’ under the hospital owner variable were considered for-profit.
Hospitals listed as either ‘Government’ or ‘Voluntary Non-profit’ were considered not-forprofit. Patients for whom we could not identify a BCS-performing hospital or whose
hospital was not included in the Hospital General Information dataset were excluded
from analyses (n=6,194, 15%). Hospital volume was calculated as the number of
patients in our sample who received surgery at each hospital during the study period.
The sample was categorized into quintiles of volume such that each quintile had
approximately the same number of patients. We assessed hospital volume to account
for any confounding association between volume and use of RT. Conceivably, higher
volume hospitals may prefer a shorter course radiation therapy modality such as
brachytherapy regardless of profit-status to ensure a target operating volume.

Patients were assigned to hospital referral regions (HRR) based on zip-code of
residence using a cross-walk available from the Dartmouth Atlas of Healthcare.49 We
assessed regional level factors that could be associated with the location of a for-profit
hospital and use of brachytherapy including the presence of a state certificate of need
(CON), two-year mammography rate, and radiation oncologist density for each HRR.
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The CON variable was used to assess the presence of policies that regulated the
opening of new radiation facilities during the study period. The presence of a state CON
was determined using the National Conference of State Legislatures online resource and
the American Health Planning Association National Directory annual report published
during our study period.50,51 We hypothesized that the presence of a state certificate of
need may affect RT use by for-profit hospitals because there may be greater barriers in
these states to open new radiation facilities and expand the referral base for radiation
delivery. We hypothesized that both two-year mammography rate, an indicator for
screening practices for a given HRR, and radiation oncologist density might be
associated with the use of RT because these regional characteristics may increase both
the incidence rate of invasive breast cancer and access to RT.

Statistical Analysis
We used chi-square tests to determine the unadjusted association between hospital
ownership and each covariate. We used hierarchical generalized linear models (HGLMs)
with a logit link function to assess the unadjusted and adjusted relationship between
hospital ownership and receipt of brachytherapy among patients who received RT.52
HGLMs allowed us to account for the non-independence of outcomes by clustering
patients within hospitals, which were clustered within HRRs. In all HGLMs, hospital and
HRR were specified as random effects, while all other covariates were specified as fixed
effects. We estimated an analogous model using receipt of any RT as our outcome in
the full sample. Because RT can be considered optional in many women ≥70 years of
age, we hypothesized that the effect of hospital ownership on receipt of any RT might be
moderated by patient age. For this reason, we repeated this model with the addition of
interaction terms between hospital ownership and age category and re-estimated the
model separately among age groups with and without significant interactions. Finally, in
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order to determine whether any association between hospital ownership and receipt of
any RT was driven primarily by the differential use of brachytherapy rather than WBI
among older women, we estimated two additional models in which the outcomes were
receipt of brachytherapy (versus no RT) and receipt of WBI (versus no RT). All data
analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC); HGLMs
were estimated using the GLIMMIX procedure.

*CCW database queries and statistical analysis using SAS were performed by Ms.
Pamela Soulos MPH.

2.4: RESULTS
Overview of Study Sample and Hospital Characteristics
Our sample included 35,118 beneficiaries who received BCS. The mean age was 74.2
(SD: 5.9) and less than 6% of our sample was above age 85. The majority of women
were white (91.1%). About 72% of the sample received adjuvant RT, of whom 22,496
(88.9%) had undergone BCS at a not-for-profit hospital and 2,816 (11.1%) at a for-profit
hospital. Among women who received RT, there were significant differences between
women receiving care at a for-profit compared to not-for-profit hospital with regards to
race, residence in a metropolitan county, median household income, and receipt of a flu
shot (Table 2.1). Patients from for-profit and not-for-profit hospitals were similar in all
other patient characteristics.

Patients received care at 2,255 not-for-profit hospitals and 429 for-profit hospitals.
Patients who received BCS at for-profit hospitals were more likely to receive surgery at
lower surgical volume hospitals and reside in states without a CON for a radiation facility
(63% of for-profit hospitals vs. 53% of not-for-profit hospitals, p<0.001). In addition,
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patients who received BCS at for-profit hospitals were more likely to reside in HRRs with
a lower mammography rate and fewer radiation oncologists per capita.

Hospital Ownership and Receipt of Brachytherapy
Among beneficiaries receiving RT, 15.7% received brachytherapy. Women at for-profit
hospitals who received RT were more likely to receive brachytherapy (20.2%) than
women at not-for-profit hospitals (15.2%, adjusted OR: 1.50, 95% CI: 1.23-1.84,
p<0.001, Table 2.2). Women who received BCS at higher surgical volume hospitals were
also more likely to receive brachytherapy. In addition, patients who had left sided
tumors, lymph node evaluation and screening mammograms were all more likely to have
received brachytherapy (p<0.001). In contrast, patients receiving chemotherapy were
less likely to receive brachytherapy.

Hospital Ownership and Receipt of Overall Radiation
There was no association between hospital ownership and the overall use of RT. That is,
73.1% of women undergoing BCS at a for-profit hospital subsequently received adjuvant
RT, compared to 72.0% of women at not-for-profit hospitals (Figure 2.1, OR: 1.08, 95%
CI: 0.97-1.20, p=0.18). However, the relation between hospital ownership and RT use
varied across age groups.
Among the oldest women (aged 80-94 years), those undergoing BCS at a for-profit
hospital were more likely to receive any RT compared to women receiving care at a notfor-profit hospital (Figure 2.1, 58.9% vs. 53.9%, OR: 1.22, 95% CI: 1.03-1.45, p=0.03).
There was no significant difference in receipt of RT according to hospital profit status
among women age 66-79 (78.1% vs. 78.8%, p=0.74)
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The increased use of RT among older women at for-profit hospitals was associated
primarily with receipt of brachytherapy. Specifically, women aged 80 and over receiving
BCS at a for-profit hospital were more likely to receive brachytherapy (12.4% at for-profit
vs. 8.0% at not-for-profit, OR for brachytherapy compared to no RT: 1.66, 95% CI: 1.182.34, p=0.003) while there was no relation between ownership status and the receipt of
WBI (46.5% at for-profit vs. 45.9% at not-for-profit, OR for WBI vs. no RT: 1.14, 95% CI:
0.96-1.36, p=0.13).
2.5: DISCUSSION
We found that Medicare beneficiaries who underwent BCS at for-profit hospitals
disproportionately received the more expensive and less proven brachytherapy over the
less expensive standard of care (WBI). Furthermore, older women (≥80) at for-profit
hospitals received more RT overall, with this difference largely driven by the use of
brachytherapy. Thus, older women received more aggressive care at for-profit hospitals,
despite being less likely to benefit from RT.9

Several factors may have contributed to the increased use of brachytherapy for women
receiving care at for-profit hospitals. Financial incentives may be one driving factor.12,40,53
Prior studies have highlighted the high reimbursement for brachytherapy, suggesting
that it is more revenue generating	
  than the standard of care. 4,42,54 While high
reimbursements do not necessarily equate to high profit margins, there has been
concern that higher reimbursements have fueled adoption of brachytherapy.4,55-57 In
response to these concerns, the Centers for Medicare and Medicaid Services reduced
reimbursement for brachytherapy in 2008 and 2010. While we do not have actual profit
margin estimates for brachytherapy in individual hospitals, our findings support previous
reports suggesting that higher reimbursements may be contributing to the rapid adoption
of brachytherapy.55-57 In other cancer care settings, it has also been suggested that
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financial incentives drive the use of newer RT modalities such as intensity modulated RT
in men with prostate cancer.5 Reduced reimbursement of chemotherapy has been
associated with significant changes in patterns of chemotherapy use by oncologists.58-60
In addition to direct financial incentives, leaders at for-profit hospitals may prefer
adopting novel therapies as a way to build market share. Indeed, hospital advertising
has been shown to promote more advanced technology as a means to attract
patients.61,62

It is important to note that a driving factor in the adoption of brachytherapy is the attempt
to enhance convenience and tolerability of treatment. Brachytherapy has the potential of
delivering RT to patients who otherwise may not seek treatment due to concerns about
treatment length and toxicity, and may be a reason for some older women to choose
brachytherapy over standard RT. However, it is unclear why patient preferences for
radiation modality would vary with hospital ownership. Given that women older than 80
years of age are least likely to benefit from radiation overall in terms of improvements in
cancer control, our analysis suggests that brachytherapy may be increasing accessibility
to RT overall, but not necessarily for women who benefit from it the most. 9,10

Our study has important limitations. First, we defined hospital ownership as either notfor-profit or for-profit which does not distinguish hospital behavior that can exist in both
profit settings.63 We grouped hospitals listed as ‘Government’ or ‘Voluntary Non-profit’ as
not-for-profit because of our hypothesis that for-profit hospitals in particular might adopt
brachytherapy to a greater extent compared to other hospital types.63 However, hospital
behavior can align with financial incentives within not-for-profit organizations as well.63,64
Therefore, coarse classification of ownership into either for-profit or not-for-profit may
obscure financial factors that affect brachytherapy use. Second, we examined only
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Medicare beneficiaries, who may not be representative of the patterns of brachytherapy
utilization in younger patient populations or in patients with private insurance or no
insurance. Third, we did not consider the decreases in the Centers for Medicare and
Medicaid Services reimbursement for breast brachytherapy, the first of which took effect
in January 2009.4 However, our study illustrates the pattern of brachytherapy use when
reimbursement was higher. While our results suggest that the year when treatment
occurred did not affect receipt of brachytherapy, future work exploring how these
changes affect brachytherapy utilization will add to our understanding of financial
incentives and adoption of new technologies of cancer care. Fourth, our analysis does
not account for provider factors such as physician reimbursement structures that may
differ between hospitals. Our analysis does not examine the effect of ownership status of
free-standing RT facilities which also provide RT for patients and may respond differently
to financial incentives. Instead, we chose to use hospital ownership where BCS was
performed because patients who are referred for RT eventually seek treatment at either
hospital-based facilities, freestanding facilities, or seek no RT treatment. Thus,
determining the effect of hospital ownership rather than RT facility ownership captures
an earlier point in the clinical decision making process. Finally, it is important to
acknowledge that the long-term risks and benefits of brachytherapy are still being
defined; the current work is focused on the adoption of brachytherapy during a time
when there was scant comparative evidence concerning either benefits or risks. Future
work should explore patterns of brachytherapy use in non-hospital based settings and
how patterns of care respond to data forthcoming from ongoing clinical trials.

Our study extends the current literature by examining how hospital ownership affects the
adoption of newer, more expensive cancer technologies and suggests that for-profit
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hospitals may be emphasizing revenue-generating RT interventions, leading to more
aggressive care in patients who are likely to benefit less from treatment.
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CHAPTER 3: COST-EFFECTIVENESS OF RADIATION THERAPY MODALITIES
3.1: ABSTRACT
PURPOSE
The use and limited benefit of radiation therapy in the clinical care of older women
with favorable risk breast cancer have raised concerns about overuse,
expenditure, and cost-effectiveness. Moreover, newer radiation therapy modalities
such as intensity modulated radiation therapy (IMRT) and brachytherapy are
diffusing into the clinical practice despite their increased costs and uncertain
clinical benefit. We used Medicare data to: (1) estimate incremental costeffectiveness ratios (ICERs) of external beam radiation therapy (EBRT) compared
to no radiation; (2) incorporate age and comorbidity into cost-effectiveness
estimates of EBRT; (3) evaluate the cost-effectiveness of newer radiation
modalities.
METHODS
Using the Surveillance, Epidemiology, and End Results-Medicare database, we
identified women who fulfilled the Cancer and Leukemia Group B C9343 trial
criteria (>70 years of age, tumor size ≤2cm, estrogen-receptor positive status,
node negative) and in whom the use of radiation can be safely omitted. We
estimated the annual recurrence, annual metastasis and determined 10-year
survival rates according to receipt of EBRT. We determined cancer-related costs
to Medicare from a payer perspective. Assuming that all radiation modalities have
equivalent effectiveness, we used a Markov decision model to calculate ICERs for
each modality compared to no radiation therapy over a 10-year time horizon. We
determined the ICERs for various radiation modalities by age and comorbidity
status.
RESULTS
The median incremental radiation-related cost associated with EBRT compared to
no radiation was $10,308. The cost-effectiveness ratio of EBRT compared to no
radiation for the full study sample was $43,015/QALY, and increased with
increasing age, ranging from $36,675 (ages 70-74) to $51,375 (ages 80-94) per
QALY. The ICER for EBRT among the oldest women with the most comorbidities
reached $343,333/QALY. The number needed to treat with radiation to prevent
one recurrence was 125. The median incremental cost was $19,254 for IMRT and
$18,249 for brachytherapy. Newer treatments would have to be at least 30% more
effective to be cost-effective.
CONCLUSIONS
EBRT is cost-effective for a many older women with early stage breast cancer, but
substantially less cost-effective for older women with multiple comorbidities.
Newer radiation modalities would have to be less costly or substantially more
effective in improving quality of life to be cost-effective.
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3.2: INTRODUCTION
While the use of external beam radiation therapy (EBRT) after breast-conserving surgery
(BCS) has been proven in clinical trials to improve local control and survival in women
with early stage breast cancer, this effect has not been shown in an elderly population
that typically has more indolent disease. 2,7,8,13,16,65-67 In fact, current trial-based
recommendations suggest that adjuvant radiation therapy may be omitted in women >70
years of age with certain low-risk tumor characteristics. 34,35 Despite these guidelines,
radiation therapy continues to be used in older women, raising concern about overuse. 11
The hesitation to change practice patterns in light of clinical evidence may be due to
both the reduction in local recurrence associated with radiation therapy and the
challenges inherent in incorporating the multifactorial effects of age and comorbidity into
decision-making.

In our resource-strained healthcare system, we must consider the substantial costs and
cost-effectiveness of radiation therapy in this population.12,40 Formal cost-effectiveness
analyses, integrating effectiveness data from well-designed clinical trials with cost data
from clinical practice, are widely used tools for informing decision-making. Yet in some
instances, new technologies diffuse into clinical practice in the absence of comparative
effectiveness data. In this context, a framework is needed to allow practitioners and
policy makers to assess newer cancer treatments in the absence of substantial clinical
data. To address this need, cost-effectiveness analysis can be used in a different way by
first traditionally assessing existing trial-tested interventions. Cost-effectiveness analysis
can then be used to project how much more effective newer interventions would have to
be in order to be cost-effective.
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Radiation therapy in the treatment of older women with breast cancer is a salient
example of a cancer technology that is continuously evolving and disseminating into
clinical practice despite limited comparative effectiveness data. 55,68 Newer and high cost
modalities such as brachytherapy and intensity modulated radiation therapy (IMRT) are
being adopted while clinical trials comparing them to the standard of care (EBRT) are
still ongoing. 4,12,16,41,55,69 These newer therapies have the potential benefits of reducing
treatment-related side effects but are substantially more costly. 13,16-18,53 Notably,
brachytherapy has not demonstrated any benefit on cancer control or overall or disease
free survival compared to EBRT and may be inferior to EBRT in subsequent mastectomy
rate and risk of complications. 19,20 IMRT has demonstrated a reduction in late toxicity
and improvement in clinical measures of breast appearance, but it is unclear how IMRT
affects patient reported quality of life. 14,70 Therefore, it is important to understand the
balance between the costs of IMRT and brachytherapy and the potential benefits of
reduced toxicity and improved cosmesis.

We therefore set out to estimate incremental cancer-related costs and cost-effectiveness
for EBRT, using actual Medicare expenditures to estimate total cancer-related costs.
Secondly, since life expectancy has a strong relation to the time at risk for breast cancer
recurrence, and therefore of the effectiveness of radiation therapy, we used actual
survival data of older women to estimate 10-year survival across life expectancy groups,
defined by age and comorbidity burden. Finally, we explored the incremental costs for
the newer radiation therapy modalities and projected how much more effective they
would have to be relative to EBRT to be cost-effective.	
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3.3: METHODS
Basic Model
We designed a Markov decision model to simulate clinical outcomes, estimate qualityadjusted life-years (QALYs) gained, and determine the incremental cost-effectiveness
ratio (ICER) of radiation therapy from a payer perspective over a 10-year horizon in older
women (≥70 years of age) with early stage breast cancer. Our base case scenario was
based on current treatment guidelines. That is, our base case scenario was of older
women with early stage breast cancer who had undergone breast-conserving surgery
but had received no radiation therapy. We used this model to compare the costs and
health benefits of various radiation modalities (EBRT, IMRT, brachytherapy) compared
to no radiation therapy. We estimated the cost-effectiveness of the newer modalities
(IMRT and brachytherapy) compared to no radiation under the assumption that they had
equal effectiveness to EBRT in terms of overall and recurrence-free survival and utility.
We then estimated the improvement in effectiveness for the newer modalities that would
be necessary in order for them to be below two commonly cited willingness to pay
thresholds of $50,000/QALY and $100,000/QALY. Three hypothetical cohorts of women
starting at ages 70, 75, and 80 were created to determine the effect of age. We assumed
that all women enter the simulation in a no recurrence health state and subsequently
transition to one of four health states (no recurrence, recurrence, metastasis, or death)
each year (Appendix 3.1). We assumed the recurrence-related decrements in utility
lasted for 2 years, during which a woman could transition to metastatic and death states
or remain in the no recurrence state.71 Alternate windows were explored in sensitivity
analysis. We chose to use a 10-year time horizon to be conservative in our assumptions
regarding the long-term benefit of radiation therapy in older women. Since current
treatment guidelines are based on the results from the C9343 trial, which has accrued
data for 10.5 years, we chose to constrain our model to a time-period during which
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radiation use has been proven to have no survival benefit. All analyses were performed
on TreeAge Pro 2012 (Williamstown, MA) and SAS version 9.2 (SAS Institute Inc., Cary,
NC).

Data Source and Model Assumptions
We determined cost inputs and transition probabilities for recurrence, metastatic, and
death states by using the National Cancer Institute’s Surveillance, Epidemiology, and
End Results (SEER)-Medicare database. Using this database, we identified a sample of
women who met eligibility criteria for the C9343 trial (≥70 years of age, tumor size ≤2cm,
estrogen-receptor positive status, lymph node negative), were diagnosed in 1998-2007,
and received BCS. The SEER-Medicare database is assembled from population-based
cancer registries and links cancer incidence and survival information with Medicare
claims 72. We selected women who fulfilled C9343 criteria because the results from this
randomized controlled trial shaped current recommendations that state radiation therapy
can be safely omitted in these older women and thus our model parameters will reflect
characteristics of a population for whom there are distinct trial based guidelines. We
estimated 10-year survival according to age group in women who were diagnosed in
1998-1999, for whom we had 10 years of follow-up data and determined an annual
mortality rate. We estimated recurrence and metastasis rates in our sample by using a
previously validated administrative algorithm.73 In brief, we used the high specificity, high
positive predictive value algorithm to identify recurrences and metastatic events in our
sample. Consistent with prior work, recurrences were estimated by determining the rate
of secondary mastectomy, which has been shown to mirror randomized clinical trial data
on effectiveness closely. 9,73 Of note, we assigned any patient with metastasis diagnosis
codes and a subsequent non-breast cancer diagnosis in SEER to the “no metastasis”
group. We used published SEER data to determine breast cancer specific mortality from
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metastatic disease and calibrated our model to obtain overall survival estimates that
were consistent with our sample survival data. 74 Our input parameters were based on a
sample of all women who fulfilled C9343 criteria but did not necessarily receive radiation
therapy to account for any selection bias in choosing women who had either received
radiation or no radiation therapy. All mortality, recurrence, and metastasis rates were
converted to annual transition probabilities as model inputs (Table 3.1).

Radiation Therapy
Patients were considered to have received radiation therapy if their Healthcare Common
Procedure Coding System codes indicated that they received at least four treatments of
EBRT or IMRT or at least one treatment of brachytherapy (Appendix 3.2). Patients with
codes for both brachytherapy and other modalities were assigned to the brachytherapy
group because they were exposed to the incremental cost as well as potential for toxicity
associated with brachytherapy.

Cost Inputs
Each cancer patient was matched to a non-cancer control based on age, race,
comorbidity, region, and year of diagnosis (or year of randomly assigned index date for
control patients). Total median costs were calculated as all costs to Medicare (including
inpatient, outpatient facility, physician, home health, hospice, and DME claims) from a
payer perspective in the 2 months before through 12 months after date of
diagnosis/index date. We used median costs instead of mean costs to be more
conservative in our cost estimates and prevent outliers from skewing the analysis. Each
cancer patient’s cancer-related cost was calculated as the difference between her total
cost and that of her matched control (Table 3.1). The costs were adjusted to 2009 US
Dollars using the Prospective Payment System and Geographic Adjustment Factor for
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inpatient services and the Medicare Economic Index and Geographic Practice Cost
Index for outpatient services. 75,76 Cost of metastatic breast cancer care in Medicare
beneficiaries was determined from the literature. 77 We estimated the continuing cost of
care in the second through ninth year after diagnosis using the same approach. Within
each year we restricted the sample used to calculate continuing cost to patients who
fulfilled the following criteria through the end of the following year: continuously enrolled
in fee-for-service Medicare and free from mastectomy, metastasis, and death. Costs in
the year before death were also calculated for all cancer patients who were continuously
enrolled in fee-for-service Medicare from diagnosis until death (Table 3.1).

Utility Inputs
We abstracted utility weights for each health state from the literature and then ageadjusted these utilities for older women at 5-year increments using previously reported
trends 63,71,78. For example, women who entered a simulation at age 70 would
experience an initial set of utilities for various health states and these utility weights
would decrease once a surviving member of the cohort turned 75 or 80. Utilities varied
based on age, receipt of radiation therapy, and metastatic and recurrence status and
were discounted at an annual rate of 3% (Table 3.1).

Life-Expectancy and Comorbidity Analysis
To assess the effect of varying survival and comorbidity burden, we constructed a
separate non-cancer sample by randomly selecting a subset of 50,000 women aged 6794 each year between 1998 and 1999 to allow for 10-year follow-up. We chose to use
survival data from a non-cancer sample to determine age and comorbidity stratified costeffectiveness estimates to allow for adequate sample size for each combination. Using
our non-cancer sample, we determined age and comorbidity combinations that
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corresponded to different 10-year survival quartiles (0-25%, 25-50%, 50-75%, 75-100%).
Combining these data, we estimated ICERs for EBRT by age and comorbidity.

Sensitivity Analysis
We performed a 1-way sensitivity analysis to assess the robustness of our model by
determining the variability in incremental cost-effectiveness as a function of cost of
radiation therapy, utility of radiation therapy, recurrence rate, metastasis rate, discount
rate, cost of recurrence, and time-span of utility decrement upon entering a recurrence
state. Recurrence and metastasis rates were varied between our estimates and trialbased data. Cost of radiation therapy was increased and decreased by 50%, the upper
limit corresponding to the cost of the newer modalities. The incremental utility benefit of
radiation therapy in both the recurrence and no recurrence state was varied by ±50%.
We varied the number of years of decreased utility after experiencing a recurrence
between one and five years. Using a threshold of $100,000/QALY, we determined how
much more effective newer radiation modalities would have to be in terms of QALYs in
order to be cost-effective.

*SEER-Medicare database queries were performed by Ms. Pamela Soulos MPH.

3.4: RESULTS
We included 18,340 Medicare beneficiaries who met the C9343 eligibility criteria. The
10-year survival among all women varied between 73.6% for women aged 70-74 and
33.4% for women aged 80-94 (Table 3.1). We estimated the annual mastectomy
probability to be 0.36% in patients receiving no radiation and 0.27% in patients receiving
radiation.
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We estimated the total costs for a 70-year old woman receiving EBRT during 10-years
follow-up to be $41,703 compared to $31,434 for no radiation, resulting in an
incremental cost of $10,269 (Table 3.2). Similarly, we estimated the QALYs experienced
for a 70-year old woman to be 7.30 for EBRT and 7.02 for no radiation resulting in an
ICER for EBRT of $36,675/QALY. ICERs for EBRT increased with increasing age, with
an 80-year old woman experiencing 5.18 QALYs with EBRT and 4.98 with no radiation,
corresponding to a cost-effectiveness ratio of $51,375/QALY. Using an age-weighted
average, we calculated cost-effectiveness of EBRT for all women in our sample to be
$43,015/QALY. The cost-effectiveness for EBRT varied by age and comorbidity status
(Figure 3.1). Older women with more comorbidity had a decreased 10-year survival
probability which corresponded to substantially less favorable cost-effectiveness for
EBRT. Specifically, the ICER for EBRT was between $33,116/QALY and $44,652/QALY
for women with predicted 10-year survival between 100% and 75% (corresponding to
women aged 70-74 with no comorbidity). The ICER for EBRT increased between
$57,122/QALY and $343,333/QALY women with predicted survival between 25% and
0%.

The median cancer-related costs per patient receiving newer radiation therapy
modalities were $25,240 for IMRT and $24,235 for brachytherapy. Compared to no
radiation, the incremental radiation-related costs were $19,254 per patient for IMRT and
$18,249 per patient for brachytherapy (Table 3.1). Compared to EBRT, the incremental
radiation-related costs were $8,946 per patient for IMRT and $7,941 per patient for
brachytherapy. Assuming the newer modalities were equally effective to EBRT, the costeffectiveness for a 70-year old woman was $68,625/QALY for IMRT and $65,036/QALY
for brachytherapy when compared with no radiation (Table 3.2). The newer modalities
were less cost-effective in 80-year old women and were estimated to be $96,105/QALY
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for IMRT and $91,080/QALY for brachytherapy. In our full sample, the cost-effectiveness
of IMRT and brachytherapy was $80,478/QALY and $76,230/QALY, respectively. The
cost-effectiveness of the newer modalities also increased with decreasing 10-year
survival probability (Figure 3.1). Specifically, the cost-effectiveness estimates for the
newer modalities were between $58,732/QALY and $79,178/QALY for women with a
predicted survival between 100% and 75%. In women with a predicted survival between
25% and 0%, the cost-effectiveness estimates increased to be between $101,239/QALY
and $608,033/QALY.

Using one-way sensitivity analyses our cost-effectiveness estimates were sensitive to
the cost of radiation therapy. The incremental cost-effectiveness ratio increased by 80%
to $65,771/QALY when the cost of EBRT was increased by 50% and approached the
cost of the newer modalities. Our estimates were also sensitive to the utility of radiation
therapy in women who had no recurrence. That is, when the incremental utility of
radiation therapy was increased by 50% in women with no recurrence, the ICER for
EBRT increased by 87% to $68,460/QALY. If we assigned zero utility benefit to radiation
therapy compared to no radiation, then the base-case scenario of no radiation
dominates our analysis. The ICER for EBRT was also sensitive to the number of years
of decreased utility after experiencing a recurrence increasing to $50,831/QALY when
we assumed the decreased utility would last for 5 years (Figure 3.2). Variations in the
other variables changed our estimates by less than 5% (Figure 3.2). We found that IMRT
and brachytherapy would have to improve QALYs by at least 28% or 56% in order to be
cost-effective with a willingness to pay threshold of $100,000/QALY or $50,000/QALY,
respectively (Figure 3.3).
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3.5: DISCUSSION
We found that EBRT is a cost-effective therapy for older women with early stage breast
cancer as the ICER of $43,015/QALY for EBRT falls below the willingness to pay
benchmark of $50,000/QALY that is typically considered acceptable 79,80. However, we
found substantial variability in the cost-effectiveness of EBRT when considering variation
in age and comorbidity. While there were many instances in which EBRT was costeffective in older women, the cost-effectiveness ratios surpassed both $50,000/QALY
and a more conservative cited benchmark of $100,000/QALY with increasing age and
comorbidity. Thus, our cost-effectiveness analysis provides one way to clarify concerns
regarding the unclear effects between life expectancy and breast cancer treatment
choices. 43

Our results raise important questions about the cost-effectiveness of IMRT and
brachytherapy. Noting the absence of effectiveness data, our model facilitated costeffectiveness estimates at various levels of clinical effectiveness. Notably, we found that
if these newer modalities had similar effectiveness to EBRT, then their ICERs are above
the benchmark of $50,000/QALY for women over 70 years with low-risk tumor
characteristics. Moreover, at their current costs these newer modalities would have to be
at least 30% more effective to be cost-effective. This study demonstrates a unique
approach to evaluating newer cancer treatments as they are diffusing into clinical
practice with limited effectiveness data. By using Medicare data to estimate both total
cancer-related costs and clinical effectiveness parameters, this approach can be more
broadly applied to other novel cancer treatments to inform patients, practitioners, and
policy makers on cost-effective care and effectiveness goals of ongoing clinical trials.
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Our study builds upon prior work by using the SEER-Medicare database to specifically
consider total cancer-related costs and clinical effectiveness of radiation therapy in a
population of older women in whom the necessity of radiation is more controversial. 81-83
In contrast, prior studies evaluating the cost-effectiveness of radiation therapy focused
on younger women (aged 55-60) in whom the benefit and necessity of radiation therapy
is more definitive and derived cost and effectiveness parameters mostly from the
literature.81-85 Our findings are consistent with prior work in that we also found EBRT to
be cost-effective in women with early stage breast cancer with an ICER of less than
$50,000/QALY. While prior work evaluating younger women estimated the ICER of
radiation therapy to be $28,000/QALY, our results suggest that EBRT is less costeffective in older women, which is not surprising given differences in survival. While our
study estimated recurrence probability to be lower than previous trials, our sensitivity
analysis suggests that these differences were minor drivers of cost-effectiveness.

There are important limitations to consider. First, our assumptions regarding utilities,
while commonly cited in the literature, do not take into consideration different recurrence
risks with current therapies, differential complication profiles of the newer therapies, and
how patient preferences and functional status change among different age groups,
factors that can all affect utility weights. 86,87 Instead, we assumed that the utilities for
each mode of radiation were equivalent which may not be accurate. The health utilities
we used were from a study in which patients reported a quality of life benefit to radiation
therapy compared to no radiation, presumably from the peace of mind that radiation
therapy allowed. Though this indicates that the long-term impact of standard breast
radiation on overall quality of life is likely low, whether it actually improves quality of life
for a patient for whom the benefit from radiation may be low is unclear. Despite the low
risk of recurrence for most older women, there is a patient-specific risk tolerance which
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must be considered. Patients who are very risk averse are unlikely to accept a higher
rate of recurrence by omitting radiation, and for these women, radiation may indeed
have a long term quality of life benefit. While we can speculate how these parameters
would affect our estimates, our projections would be strengthened with more information
on how the utility function is affected by these parameters and with long-term data
regarding the efficacy of these newer modalities.

Furthermore, studying cost-effectiveness using a cohort of long surviving patients may
place less emphasis on short-term complications. Therefore, if patients place great
importance on avoiding short-term toxicity or upon shorter radiation schedules (such as
with brachytherapy), they may feel that more expensive treatment is justified, despite a
lack of a large benefit as measured by improvement in the QALY forecast. For example,
if brachytherapy is associated with less severe acute skin reactions compared to EBRT,
this may lead to a transiently increased utility for brachytherapy. Despite this increased
utility, however, the effect on the QALY forecast is likely minimal due to the relatively
transient nature of skin reactions. In contrast, if brachytherapy significantly improves
long-term breast outcomes such as cosmesis or late effects on the lung and heart, the
effect on QALYs could be more significant. Other factors that may affect long-term utility
and cost of these newer modalities include subsequent related procedures, screening
and late toxicity. For example, several studies have reported that patients receiving
brachytherapy receive more surgery post therapy while others have pointed out that a
subset of patients have persistent seromas that may require ultrasound or even excision.
88-90

For IMRT, ongoing randomized controlled trials have reported a reduction in acute

and long-term toxicity. 14 Therefore, if these factors change the utility or long-term costs
of the newer modalities, then the target effectiveness will have to change
correspondingly in order for these modalities to be cost-effective.
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We also assumed that the recurrence risk is equivalent across all modalities. This is a
tenuous assumption because brachytherapy may be less capable of treating occult
multifocal disease compared to EBRT and is more prone to marginal miss (missing
occult microscopic extension just beyond the excision cavity), which would ultimately
lead to a larger difference in cost-effectiveness relative to EBRT. 91 Evidence from
ongoing trials, thus, will be important to accurately build upon this model and to evaluate
newer RT modalities.

In summary, EBRT is cost-effective for most older women with early stage breast
cancer. However, newer modalities such as IMRT and brachytherapy are costlier than
EBRT and would have to be substantially more effective in improving cancer control or
quality of life to achieve equivalent cost-effectiveness. As newer technologies
disseminate into clinical practice, it will be important to provide data on comparative
effectiveness relative to costs to better inform clinical decision-making.
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CHAPTER 4: CONCLUSIONS & FUTURE DIRECTIONS

	
  
4.1: SUMMARY
We assessed the effect of hospital ownership status on the adoption of brachytherapy
and estimated cost-effectiveness of new radiation technologies in the treatment of older
women with breast cancer. We found that hospital for-profit status was related to the
receipt of not only brachytherapy but also was related to higher overall radiation therapy
use leading to potentially overly aggressive care in this population. We also found that
while the current standard of care, EBRT, is relatively cost-effective for older women,
newer modalities would have substantially improve quality of life or be more effective in
order to be cost-effective. We also found that cost-effectiveness of radiation therapy
modalities vary substantially with increasing age and comorbidity. Overall, the increased
adoption of these newer therapies in older women raises important questions about not
only cost-effective care but also about provider preferences and financial incentives that
may promote use despite limited data on effectiveness.

4.2: FUTURE DIRECTIONS
For-Profit Ownership and Receipt of Brachytherapy
While several factors may be related to the association between for-profit hospital
ownership and receipt of brachytherapy, financial incentives may be one factor that can
be tested further . Policy changes have led to decreased reimbursement and changes in
coding structure for brachytherapy in breast cancer care. 4 Specifically, in 2008 Medicare
reimbursement for each treatment delivered decreased. Also, the reimbursement
structure changed to compensate number of catheters used instead of the number of
dwell positions. In 2010, surgeon reimbursement for brachytherapy device placement
was also decreased. These two events enable an interesting experiment to assess the
role of financial incentives. That is, if financial incentives were driving increased use of
brachytherapy in older women then decreases in reimbursement may lead to decreased
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use. On the other hand, if financial incentives are at play, then decreases in
reimbursement may lead to changes in practice patterns in order to protect
remuneration. For example, in order to protect compensation to levels commensurate
with earlier reimbursement levels, practice patterns may shift towards more numerous
catheter placement. However, if financial incentives are not driving increased
brachytherapy use, then these effects may not be observed. Finally, determining the
association between for-profit ownership status of free-standing radiation facilities and
brachytherapy use may be another meaninful experiment to test the effect of financial
incentives because free-standing radiation facilities may be more directly responsive to
financial incentives than hospitals.
Cost-Effectiveness of Newer Radiation Therapy Modalities
We found that our cost-effectiveness estimates were particularly sensitive to utilities
assigned to the various health states in our model. However, there is limited data
characterizing utilities in women with early stage breast cancer receiving radiation
therapy. We used utilities derived from the literature which may be dated and may not as
accurately reflect the current perception of radiation therapy. The utilities used in our
work also reflect a net benefit of radiation therapy over no radiation which is debatable in
an older population given current evidence. Also, there have been no studies to our
knowledge that have determined the utility of radiation therapy in older women
specifically or the utility of the newer modalities. Thus, it will be important to direct future
work towards understanding how older women percieve both the standard of care as
well as the newer radiation modalities in terms of quality of life. In addition to the effects
of age and technology, utility may change based on period in diagnosis, treatment, and
post-treatment which will affect cost-effectiveness estimates. Finally, up to date utilities
may be particularly important in characterizing the newer modalities which have many
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touted benefits in terms of toxicity and adverse effects. Together, these data will be
important to strengthen future cost-effectiveness analyses and convey a more accurate
and to date perception of the quality of life benefits of radiation therapy. However,
collecting utility data can be laborious and challenging. Future work using existing survey
instruments such as the Short Form (36) Health Survey (SF-36) may be one way to
address this need because there are validated algorithms that are able to transform SF36 data into utilities. 92 Conceivably, using this survey instrument we will be able to
derive chronological changes in utility during various stages of cancer care for various
radiation therapy modalities in women of varying ages. Finally, future work incorporating
future trial-based effectiveness data will be critical to re-assessing cost-effectiveness of
various radiation therapy modalities.
4.3: CONCLUSIONS
Proper evaluation of new technologies that considers benefits, risks, and costs in
specific populations is critical towards promoting appropriate clinical care. As new
technologies continually emerge into clinical practice, it will be important to
comprehensively assess factors driving adoption, incentives affecting clinical decision
making, and ultimately patient outcomes. Careful and thorough evaluation has
influential consequences in spuring discussion and shaping policies that have positive
impact on patient safety, quality, and outcome.
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Table 2.1: Characteristics of patients who received radiation therapy according to
hospital ownership where breast-conserving surgery was performed
Table 2.2: Associations between patient, clinical, and health system characteristics and
the receipt of brachytherapy. Adjusted for patient, clinical, and health system
characteristics
Table 3.1: Cost-Effectiveness Model Input Parameters
Table 3.2: Cost-Effectiveness Estimates
Figure 2.1: Percent of women receiving any radiation therapy or brachytherapy based
on age and hospital ownership. NFP: not-for-profit; FP: for-profit
Figure 3.1: Cost-Effectiveness of EBRT and Newer Modalities based on Patient Age
and Comorbidity (for example, a patient who is 77 years old with 1 comorbidity has a 10year survival that falls between 25-50%. For EBRT, this estimated 10-year survival
probability corresponds to a cost-effectiveness ratio between $44,678/QALY and
$68,547/QALY.)
Figure 3.2: One way sensitivity analysis for EBRT in women aged 70-74
Figure 3.3: Incremental benefit in QALYs for newer modalities to be cost-effective

Appendix 2.1: Procedure and diagnosis codes used in analysis
Appendix 2.2: Sample selection algorithm
Appendix 3.1: Basic Model Bubble Diagram
Appendix 3.2: HCPCS and ICD-9 codes used in analysis
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FIGURE 2.1 Percent of women receiving any radiation therapy or brachytherapy based on age
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FIGURE 3.1: Cost-Effectiveness of EBRT and Newer Modalities based on Patient Age and
Comorbidity (for example, a patient who is 77 years old with 1 comorbidity has a 10-year
survival that falls between 25-50%. For EBRT, this estimated 10-year survival probability
corresponds to a cost-effectiveness ratio between $44,678/QALY and $68,547/QALY.)

Age

Comorbidity
3+
1-2
0

70-74

50-75%

>75%

75-79

25-50%

50-75%

80-84
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85-94
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10 Year Survival Probability

	
  
	
  

100,000

150,000 300,000

600,000

EBRT
Brachytherapy

*Conditions used to create comorbidity categories included congestive heart failure, cardiac
arrhythmias, valvular disease, pulmonary circulation disorders, peripheral vascular disorders,
paralysis, other neurological disorders, chronic pulmonary disease, diabetes, renal failure, liver
disease, AIDS/HIV, lymphoma, metastatic cancer, solid tumor without metastasis, rheumatoid
arthritis/collagen, coagulopathy, weight loss, fluid and electrolyte disorders, deficiency anemia,
alcohol abuse, drug abuse, psychoses, depression.
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FIGURE 3.2: One way sensitivity analysis for EBRT in women aged 70-74

Cost of RT (0.5x - 1.5x)
Utility of RT with No Recurrence (0.5x - 1.5x)
Number of Years of Decreased Utility
After Recurrence (1-5 yrs)
Probability of Metastasis (0-2x)
Recurrence Probability (no RT)
(SEER Medicare to C9343)
Utility of RT with Recurrence (0.5x - 1.5x)
Recurrence Probability (RT)
(SEER Medicare to C9343)

5,
00
0
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,0
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,0
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35
,0
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45
,0
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55
,0
00
65
,0
00
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,0
00

Cost of Recurrence (0-2x)

$/QALY

*the incremental utility benefit of RT (versus no RT) in either a recurrence or no recurrence state
was varied by ±50%
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Incremental QALY Benefit (%)

FIGURE 3.3: Incremental benefit in QALYs for newer modalities to be cost-effective
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Table 2.1 Characteristics of patients who received radiation therapy according to ownership of
the hospital where breast-conserving surgery was performed.

Total
Hospital characteristics
Hospital volume
Q1 (1-7)
Q2 (8-14)
Q3 (15-22)
Q4 (23-38)
Q5 (39-142)
Patient Characteristics
Age at breast-conserving surgery
66-69
70-74
75-79
80-84
85-94
Race
White
Black
Other
Year of surgery
2008
2009
Residence in metro county
Yes
No
Clinical characteristics
Comorbidity
0 conditions
1-2 conditions
≥3 conditions
Tumor laterality
Right-sided
Left-sided
Unknown
Axillary node dissection
No
Yes

Non-profit
N
%
22496

For-profit
N
%
2816

p-value

<0.001
4170
4284
4347
5013
4682

18.5
19.0
19.3
22.3
20.8

855
862
445
338
316

30.4
30.6
15.8
12.0
11.2

5964
6673
5209
3412
1238

26.5
29.7
23.2
15.2
5.5

765
834
619
428
170

27.2
29.6
22.0
15.2
6.0

20542
1375
579

91.3
6.1
2.6

2517
183
116

89.4
6.5
4.1

14610
7886

64.9
35.1

1823
993

64.7
35.3

18038
4458

80.2
19.8

2330
486

82.7
17.3

12761
7995
1740

56.7
35.5
7.7

1584
1021
211

56.3
36.3
7.5

9715
10056
2725

43.2
44.7
12.1

1227
1228
361

43.6
43.6
12.8

6285
16211

27.9
72.1

740
2076

26.3
73.7

0.53

<0.001

0.83

0.001

0.72

0.41

0.06
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Chemotherapy
No chemotherapy
Chemotherapy started in month prior
through month after surgery
Chemotherapy started in 31-365 days
after surgery
Hospital admission*
No
Yes
Screening mammogram*
No
Yes
Flu shot*
No
Yes
Visit to primary care physician*
No
Yes
Health system characteristics
State certificate of need for radiation
facility
No
Yes
HRR-level two-year mammography
rate among female Medicare
enrollees 67-69, in quintiles
Q1 (50.1-59.7)
Q2 (59.8-62.4)
Q3 (62.4-64.9)
Q4 (65.0-68.4)
Q5 (68.4-76.1)
Radiation oncologist density per
100,000 residents, in quintiles
Q1 (0.2-1.0)
Q2 (1.0-1.1)
Q3 (1.1-1.2)
Q4 (1.2-1.4)
Q5 (1.4-2.5)
*In year prior to breast-conserving surgery

Non-profit
N
%

For-profit
N
%

19721
920

87.7
4.1

2429
115

86.3
4.1

1855

8.3

272

9.7

19460
3036

86.5
13.5

2435
381

86.5
13.5

5102
17394

22.7
77.3

683
2133

24.3
75.8

9390
13106

41.7
58.3

1242
1574

44.1
55.9

686
21810

3.1
97.0

71
2745

2.5
97.5

11820
10676

52.5
47.5

1773
1043

63.0
37.0

3941
4400
4652
4762
4741

17.5
19.6
20.7
21.2
21.1

793
706
468
441
408

28.2
25.1
16.6
15.7
14.5

4397
4078
4531
4818
4672

19.6
18.1
20.1
21.4
20.8

688
660
624
293
551

24.4
23.4
22.2
10.4
19.6

p-value
0.04

0.96

0.06

0.02

0.12

<0.001

<0.001

<0.001
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Table 2.2 Associations between patient, hospital, and health system characteristics and the receipt of brachytherapy
Percent
Unadjusted
Adjusted
Receiving
OR
95% CI
P-value
OR
95% CI
P-value
Brachytherapy
Hospital characteristics
Hospital profit status
0.01
<0.001
Non-profit
15.2
1.00
--1.00
--For-profit
20.2
1.28
1.06
1.55
1.50
1.23
1.84
Hospital volume
<0.001
<0.001
Q1 (1-7)
9.1
1.00
--1.00
--Q2 (8-14)
13.2
1.40
1.15
1.69
1.38
1.13
1.67
Q3 (15-22)
16.6
1.98
1.61
2.43
2.02
1.64
2.50
Q4 (23-38)
20.0
2.21
1.79
2.72
2.24
1.80
2.77
Q5 (39-142)
19.6
1.93
1.53
2.44
2.00
1.57
2.53
Patient characteristics
Age at BCS
0.52
66-69
16.0
1.00
--70-74
15.6
0.99
0.89
1.09
75-79
15.8
0.97
0.86
1.08
80-84
15.7
0.90
0.80
1.03
85-94
15.3
0.91
0.76
1.09
Race
0.02
0.06
White
15.9
1.00
--1.00
--Black
13.2
0.77
0.65
0.92
0.81
0.67
0.97
Other
15.0
0.99
0.77
1.27
1.04
0.80
1.33
Year of surgery
0.53
2008
15.7
1.00
--2009
15.8
0.97
0.90
1.06
Residence in metro county
0.51
Yes
16.4
1.00
--No

12.9

0.96

0.84

1.09
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Clinical characteristics
Comorbidity
0 conditions
1-2 conditions
≥3 conditions
Tumor laterality
Right sided
Left sided
Unknown
Axillary node dissection
No
Yes
Chemotherapy (composite)
No chemotherapy
Chemotherapy started in
month prior through month
after surgery
Chemotherapy started in 31365 days after surgery
Hospital admission
(year prior to surgery)
No
Yes
Screening mammogram
(year prior to surgery)
No
Yes
Flu shot
(year prior to surgery)
No
Yes

	
  

Percent
Receiving
Brachytherapy

Unadjusted
OR

15.6
16.0
15.4

1.00
1.03
0.96

95% CI

Adjusted
P-value

OR

95% CI

P-value

0.59
-0.95
0.83

-1.12
1.12
<0.001

15.6
16.7
12.9

1.00
1.10
0.81

-1.02
0.71

-1.20
0.93

<0.001
1.00
1.11
0.83

-1.02
0.72

-1.21
0.96

<0.001
11.6
17.3

1.00
1.46

-1.32

-1.60

<0.001
1.00
1.52

-1.38

-1.68

<0.001

<0.001

16.3
7.2

1.00
0.33

-0.25

-0.43

1.00
0.32

-0.24

-0.41

13.8

0.73

0.63

0.84

0.70

0.61

0.82

0.04
15.9
14.3

1.00
0.89

-0.79

-1.00
<0.001

13.4
16.4

1.00
1.45

-1.32

-1.60

1.00
1.44
0.34

15.4
16.0

1.00
1.04

-0.96

-1.13

<0.001
-1.30

-1.59
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Percent
Receiving
Brachytherapy
Visit to PCP
(year prior to surgery)
No
Yes
Health system characteristics
State CON for radiation facility
No
Yes
HRR-level two-year
mammography rate among
female Medicare enrollees 67-69,
in quintiles
Q1 (50.1-59.7)
Q2 (59.8-62.4)
Q3 (62.4-64.9)
Q4 (65.0-68.4)
Q5 (68.4-76.1)
Radiation oncologist density per
100,000 residents, in quintiles
Q1 (0.2-1.0)
Q2 (1.0-1.1)
Q3 (1.1-1.2)
Q4 (1.2-1.4)
Q5 (1.4-2.5)

Unadjusted
OR

95% CI

Adjusted
P-value

OR

95% CI

P-value

0.03
12.0
15.8

1.00
1.32

-1.03

-1.71

0.09
17.5
13.6

1.00
0.85

-0.71

-1.02
0.04

17.1
17.2
16.3
16.1
12.0

1.00
1.05
0.92
0.80
0.67

-0.76
0.67
0.58
0.49

-1.44
1.27
1.10
0.92

0.007

1.00
1.04
0.89
0.75
0.62

-0.76
0.64
0.55
0.45

-1.44
1.23
1.04
0.85

0.26
1.00
0.92
0.85
0.84
0.70

-0.69
0.63
0.63
0.51

-1.23
1.16
1.13
0.96

*Adjusted for the following health system characteristics: state certificate of need (CON), HRR level 2-year mammography rate in
quintiles, and radiation oncologist density per 100,000 enrollees
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Table 3.1 Model Inputs
Model Assumptions
Utilities
Conservative Surgery and Radiation Therapy with No Recurrence
Conservative Surgery and Radiation Therapy with Isolated Local Recurrence
Conservative Surgery Alone with No Radiation Therapy with No Recurrence*
Conservative Surgery Alone with No Radiation Therapy with Isolated Local Recurrence*
Distant Metastases
Survival (All Women)
5 year survival
70-74
75-79
80-94
10-year survival
70-74
75-79
80-94
Annual Recurrence Probability
No RT*
RT
Annual Metastasis Probability
1-3 years
4-10 years
Annual Death Probability from Metastatic Breast Cancer
Annual Discount Rate
Cancer Related Costs per patient
No RT*
EBRT
IMRT
Brachytherapy
Other Costs
Recurrence (Mastectomy)
Metastatic Care
Continued Phase Costs
Death (last year of life)
* Base case estimate

	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

Ref

71, 78

0.92-0.758
0.82-0.676
0.88-0.725
0.81-0.667
0.7-0.577

91.1%
86.6%
70.3%
73.6%
61.2%
33.4%
0.0036
0.0027
0.0064
0.0096
0.210-0.238
3%

74

$5,986
$16,294
$25,240
$24,235
$5,534
$35,000
$156-$705
$28,580

77
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Table 3.2 Cost and Effectiveness Estimates

Costs ($)

ΔQALY

Incremental
Cost-Effectiveness Ratio
($/QALY)*

Number Needed to Treat to
Prevent One Recurrence

Age

No RT

EBRT

IMRT

Brachytherapy

70-74

31,434

41,703

50,649

49,644

75-79

40,907

51,177

60,123

59,118

80-94

71,803

82,078

91,024

90,019

70-74

-

0.28

(0.28)

(0.28)

75-79

-

0.25

(0.25)

(0.25)

80-94

-

0.20

(0.20)

(0.20)

70-74

-

36,675

68,625

65,036

75-79

-

41,080

76,864

72,844

80-94

-

51,375

96,105

91,080

All

-

43,015

80,478

76,270

All

-

125

- denotes base case scenario;
italics indicates model assumption that effectiveness of newer modalities is the same as EBRT
* Incremental Cost-Effectiveness Ratios for newer modalities (IMRT, brachytherapy) are compared to no RT
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APPENDICES
APPENDIX 2.1 Procedure and diagnosis codes used in analysis

Breast Surgery

Whole-Breast Irradiation

Brachytherapy

Tumor laterality
Axillary node dissection

Chemotherapy

Screening mammogram

Flu shot

Visit to primary care physician

	
  

HCPCS
19110, 19120,
19125, 19126,
19160, 19162,
19301, 19302
77402, 77403,
77404, 77406,
77407, 77408,
77409, 77411,
77412, 77413,
77414, 77416,
77418, 0073T,
G0174
77761, 77762,
77763, 77776,
77777, 77778,
77781, 77782,
77783, 77784,
77785, 77786,
77787, 77799,
0182T

ICD-9 PROCEDURE

ICD-9 DIAGNOSIS

85.20, 85.21, 85.22,
85.23, 85.25,

This was using the
HCPCS modifier
codes for left and
right side, which is
optionally included
for procedures
19302, 38740,
38745, 38525,
38500

40.23, 40.51

96400-96549,
Q0083-Q0085,
J9000-J9999,
G0355-G0362,
J8510, J8520,
J8521, J8530,
J8560, J8565,
J8600, J8610,
J8700

99.25

76092, 77057,
G0202, G0203

V58.1
V76.1, V76.11,
V76.12

90656, 90658, 90659,
90660, 90661, 90662,
90724
99202, 99203, 99204,
99205, 99212, 99213,
99214, 99215, 99387,
99397

V04.81
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APPENDIX 2.2 Sample Selection Algorithm
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APPENDIX 3.1

±RT

Women with
Early Stage
Breast Cancer

	
  

	
  
Recurrence

pRecurrence

*

pMetastasis

pMetastasis
Metastasis

	
  

	
  

	
  
pDeath
(metastatic cancer)

pDeath
(background)

Death

pDeath
(background)

*Upon experiencing a recurrence, there is a two-year decrease in utility
pDeath (background): annual probability of death (refers to background mortality)
pDeath (metastatic cancer): annual probability of death from metastatic breast cancer
pRecurrence: annual probability of recurrence
pMetastasis: annual probability of metastasis

	
  

	
  

No
Recurrence
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APPENDIX 3.2

Treatment
Breast-conserving surgery
External beam radiation
therapy
Intensity modulated
radiotherapy
Brachytherapy

	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

	
  

Healthcare Common
Procedure Coding System

International Classification
th
of Diseases, 9 revision

19110, 19120, 19125, 19126,
19160, 19162, 19301, 19302

85.20, 85.21, 85.22, 85.23,
85.25,

77402, 77403, 77404, 77406,
77407, 77408, 77409, 77411,
77412, 77413, 77414, 77416,
77301, 77418, 0073T, G0174
77761, 77762, 77763, 77776,
77777, 77778, 77781, 77782,
77783, 77784, 77799, 0182T,
19296, 19297, 19298, C9714,
C9715
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